We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
Shares of Acceleron Pharma Inc. (XLRN) are moving higher in Friday's market, following the U.S. Food and Drug Administration's announcement it had approved Reblozyl for the treatment of anemia patients with beta thalassemia who require regular red blood cell transfusions.
Celgene Corp. (CELG) and Acceleron are jointly developing Reblozyl, the companies said.
At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade at $43.05.
Celgene shares were up 0.35%, to $109.38, following the news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2019 13:15 ET (18:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
